RECBIO-B (02179) announced its interim results for 2025, reporting continuing operations revenue of 10.899 million yuan (RMB, same below), compared to nil in the same period last year. Loss attributable to owners of the parent company reached 341 million yuan, representing a 36.7% increase year-on-year. Basic loss per share was 0.71 yuan. The year-on-year revenue increase was primarily attributed to income generated from intellectual property licensing granted by the company during the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments